|
| Friday, February 16, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate). more info >> |
|
| Thursday, February 1, 2024 |
|
|
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa |
| Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa. more info >> |
|
| Friday, January 26, 2024 |
|
|
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan. more info >> |
|
| Thursday, January 18, 2024 |
|
|
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan |
| Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. more info >> |
|
| Wednesday, January 17, 2024 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time |
| Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Tuesday, January 16, 2024 |
|
|
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 |
| Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually. more info >> |
|
|
エーザイ、ASCO GI および ASCO GU において複数のがんに対する最新の開発研究に関する演題を発表 |
| more info >> |
|
| Thursday, January 11, 2024 |
|
|
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU |
| Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing authorization application (MAA) of lecanemab (generic name, brand name: LEQEMBI), which is currently under review by the European Medicines Agency (EMA). more info >> |
|
| Wednesday, January 10, 2024 |
|
">
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China
|
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. ">more info >> |
|
| Friday, December 29, 2023 |
|
|
Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor |
| Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta (Abeta) accumulation in the brain using a wristband sensor. more info >> |
|
|
|
|
